Bezisterim

Bezisterim
Clinical data
Other names	NE3107; NE-3107; HE3286; HE-3286; 17α-Ethynyl-5-androstene-3β,7β,17β-triol;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (3S,7R,8R,9S,10R,13S,14S,17R)-17-Ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,7,17-triol;
CAS Number	1001100-69-1;
PubChem CID	16739648;
DrugBank	DB05212;
ChemSpider	20571043;
UNII	PH8858757I;
KEGG	D12932;
ChEMBL	ChEMBL4297284;
CompTox Dashboard (EPA)	DTXSID501267252 ;
Chemical and physical data
Formula	C21H30O3
Molar mass	330.468 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CC[C@@H](CC1=C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O)O;
	InChI InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1; Key:JJKOQZHWYLMASZ-FJWDNACWSA-N;

Bezisterim (developmental code names NE3107, HE3286) is a synthetic analogue of androstenetriol that is believed to have anti-inflammatory and insulin-sensitizing effects in the brain. The compound crosses the blood–brain barrier and does not activate any neurotransmitter receptors. It has been tested as a treatment for Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The drug is under development for a variety of conditions and its highest developmental phase is phase 3 for Alzheimer's disease.